The Department of the Navy Bureau of Medicine and Surgery awarded an Indefinite Delivery Contract (IDC) worth up to $3,332,295.75 to Illumina, Inc., a manufacturer of genomic sequencing systems and reagents. Under this single-award IDC, Illumina will provide nucleic acid sequencing reagents and positive controls for MiSeq, iSeq, NextSeq, and NovaSeq6000 sequencing instruments used by the Naval Medical Research Center's Biological Defense Research Directorate (NMRC-BDRD) to characterize biological threats to U.S. military personnel.
A $114,751.84 fixed-price with economic price adjustment delivery order was issued to Illumina for sequencing reagents and controls to be delivered by June 29, 2023. The original solicitation was a special notice posted on December 3, 2022 with a HUBZone set-aside, seeking a sole-source award to Illumina as the sole manufacturer of the required sequencing instruments and proprietary reagents. The contracted goods and services support NMRC-BDRD's mission of rapid and efficient genomic analysis to identify biological threats faced by the U.S. military.